David G. Kalergis
Founder at Diffusion Pharmaceuticals LLC
Profile
David G.
Kalergis is the founder of Diffusion Pharmaceuticals LLC, where he currently serves as the Chief Executive Officer & Director since 2004.
He was also the founder of Diffusion Pharmaceuticals, Inc., where he served as the Chairman from 2020 to 2021.
Mr. Kalergis has held former positions as the Chairman & Chief Executive Officer of RestorGenex Corp., Founding Director of Virginia National Bank (Charlottesville) from 1998 to 2012, Director of Virginia Biotechnology Association, General Counsel & Head-Business Development of Pharmaceutical Research Associates, Inc. from 1994 to 1998, General Counsel of the University of Virginia from 1998 to 2004, and President & General Counsel of Designs Import Export Ltd.
from 1986 to 1990.
He obtained a graduate degree and an MBA from the University of Virginia, and an undergraduate degree in 1970 from the same institution.
Mr. Kalergis is also the founder of Atelerix Life Sciences, Inc...
David G. Kalergis active positions
Companies | Position | Start |
---|---|---|
Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Diffusion Pharmaceuticals LLC develops and manufactures pharmaceutical products. The firm develops trans sodium crocetinate for use in cancers types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. The company was founded by Matthew W. Hantzmon, John L. Gainer, and David G. Kalergis in February 2001 and is headquartered in Charlottesville, VA. | Founder | 01/02/2001 |
Atelerix Life Sciences, Inc.
Atelerix Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Atelerix Life Sciences, Inc. is a pharmaceutical company that is developing a new drug, ATLX-0199, to address the unmet need of opioid-induced respiratory depression (OIRD) in surgical patients. The company is based in Charlottesville, VA. Atelerix Life Sciences was founded by David G. Kalergis, Benjamin Gaston, James Bates, and Stephen Lewis, with David G. Kalergis serving as the CEO since incorporation. The current drug for OIRD, Naloxone, is problematic and used infrequently because it reverses pain relief. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia. | Chief Executive Officer | - |
Former positions of David G. Kalergis
Companies | Position | End |
---|---|---|
DIFFUSION PHARMA | Chief Executive Officer | 08/09/2020 |
Virginia National Bank (Charlottesville)
Virginia National Bank (Charlottesville) Major BanksFinance Virginia National Bank provides banking and financial services. The firm operates through two segments: The Commercial Bank and VNB Trust. The Commercial Bank segment involves making loans and generating deposits from individuals and businesses. The VNB Trust segment offers services, which include investment management, trust account administration and estate planning. It offers personal banking, business banking and treasury management services. The company was founded on July 29, 1998 and is headquartered in Charlottesville, VA. | Director/Board Member | 01/05/2012 |
University of Virginia | General Counsel | 01/01/2004 |
Pharmaceutical Research Associates, Inc.
Pharmaceutical Research Associates, Inc. Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Research Associates, Inc. engages in the provision of clinical research services. It focuses on therapeutic, global regulatory affairs, and pharmacovigilance and patient safety. The company was founded in 1982 and is headquartered in Raleigh, NC. | Director/Board Member | 01/01/1994 |
Designs Import Export Ltd. | President | 01/01/1990 |
Training of David G. Kalergis
University of Virginia | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 8 |
---|---|
Virginia National Bank (Charlottesville)
Virginia National Bank (Charlottesville) Major BanksFinance Virginia National Bank provides banking and financial services. The firm operates through two segments: The Commercial Bank and VNB Trust. The Commercial Bank segment involves making loans and generating deposits from individuals and businesses. The VNB Trust segment offers services, which include investment management, trust account administration and estate planning. It offers personal banking, business banking and treasury management services. The company was founded on July 29, 1998 and is headquartered in Charlottesville, VA. | Finance |
Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Diffusion Pharmaceuticals LLC develops and manufactures pharmaceutical products. The firm develops trans sodium crocetinate for use in cancers types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. The company was founded by Matthew W. Hantzmon, John L. Gainer, and David G. Kalergis in February 2001 and is headquartered in Charlottesville, VA. | Health Technology |
Pharmaceutical Research Associates, Inc.
Pharmaceutical Research Associates, Inc. Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Research Associates, Inc. engages in the provision of clinical research services. It focuses on therapeutic, global regulatory affairs, and pharmacovigilance and patient safety. The company was founded in 1982 and is headquartered in Raleigh, NC. | Commercial Services |
Designs Import Export Ltd. | |
Virginia Biotechnology Association
Virginia Biotechnology Association Miscellaneous Commercial ServicesCommercial Services Virginia Biotechnology Association promotes the biotechnology industry. The private company is based in Richmond, VA. The company was founded in 1992 by Terry R. Woodworth. John L. Newby has been the CEO of the company since 2019. | Commercial Services |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | Health Technology |
Diffusion Pharmaceuticals, Inc.
Diffusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA. | Health Technology |
Atelerix Life Sciences, Inc.
Atelerix Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Atelerix Life Sciences, Inc. is a pharmaceutical company that is developing a new drug, ATLX-0199, to address the unmet need of opioid-induced respiratory depression (OIRD) in surgical patients. The company is based in Charlottesville, VA. Atelerix Life Sciences was founded by David G. Kalergis, Benjamin Gaston, James Bates, and Stephen Lewis, with David G. Kalergis serving as the CEO since incorporation. The current drug for OIRD, Naloxone, is problematic and used infrequently because it reverses pain relief. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia. | Health Technology |
- Stock Market
- Insiders
- David G. Kalergis